Chao Zhang1, Jianjun Zhang2, Fang-Ping Xu3, Yin-Guang Wang4, Zhi Xie5, Jian Su5, Song Dong5, Qiang Nie5, Yang Shao6, Qing Zhou5, Jin-Ji Yang5, Xue-Ning Yang5, Xu-Chao Zhang5, Zhi Li3, Yi-Long Wu5, Wen-Zhao Zhong7. 1. Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China; School of Medicine, South China University of Technology, Guangzhou, People's Republic of China. 2. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Department of Genomic Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. 3. Department of Pathology, Guangdong Provincial Peoples' Hospital, Guangzhou, People's Republic of China. 4. Nanjing Geneseeq Technology Inc., Najing, Jiangsu, People's Republic of China. 5. Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. 6. Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada. 7. Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address: 13609777314@163.com.
Abstract
BACKGROUND: Understanding the genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma may provide critical insight and facilitate development of novel strategies for early detection and intervention. METHODS: A total of 80 tumor tissue samples and 30 paired histologically normal lung tissue samples from 30 patients with adenocarcinoma in situ (AIS) (n = 8), minimally invasive adenocarcinoma (MIA) (n = 8), and invasive adenocarcinoma (IAC) (n = 14) were subjected to multiregion whole exome sequencing and immunohistochemistry staining for CD8 and programmed death ligand 1 (PD-L1). RESULTS: All tumors, including AIS, exhibited evidence of genomic intratumor heterogeneity. Canonical cancer gene mutations in EGFR, erb-b2 receptor tyrosine kinase 2 gene (ERBB2), NRAS, and BRAF were exclusively trunk mutations detected in all regions within each tumor, whereas genes associated with cell mobility, gap junction, and metastasis were all subclonal mutations. EGFR mutation represented the most common driver alterations across AIS, MIA, and IAC, whereas tumor protein p53 gene (TP53) was identified in MIA and IAC but not in AIS. There was no difference in PD-L1 expression among AIS, MIA, and IAC, but the CD8 positivity rate was higher in IAC. Tumors positive for both PD-L1 and CD8 had a larger proportion of subclonal mutations. CONCLUSIONS: Mutations in EGFR, ERBB2, NRAS, and BRAF are early clonal genomic events during carcinogenesis of lung adenocarcinoma, whereas TP53 and cell mobility, gap junction, and metastasis-related genes may be late events associated with subclonal diversification and neoplastic progression. Genomic intratumor heterogeneity and immunoediting are common and early phenomena that may have occurred before the acquisition of invasion.
BACKGROUND: Understanding the genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma may provide critical insight and facilitate development of novel strategies for early detection and intervention. METHODS: A total of 80 tumor tissue samples and 30 paired histologically normal lung tissue samples from 30 patients with adenocarcinoma in situ (AIS) (n = 8), minimally invasive adenocarcinoma (MIA) (n = 8), and invasive adenocarcinoma (IAC) (n = 14) were subjected to multiregion whole exome sequencing and immunohistochemistry staining for CD8 and programmed death ligand 1 (PD-L1). RESULTS: All tumors, including AIS, exhibited evidence of genomic intratumor heterogeneity. Canonical cancer gene mutations in EGFR, erb-b2 receptor tyrosine kinase 2 gene (ERBB2), NRAS, and BRAF were exclusively trunk mutations detected in all regions within each tumor, whereas genes associated with cell mobility, gap junction, and metastasis were all subclonal mutations. EGFR mutation represented the most common driver alterations across AIS, MIA, and IAC, whereas tumor protein p53 gene (TP53) was identified in MIA and IAC but not in AIS. There was no difference in PD-L1 expression among AIS, MIA, and IAC, but the CD8 positivity rate was higher in IAC. Tumors positive for both PD-L1 and CD8 had a larger proportion of subclonal mutations. CONCLUSIONS: Mutations in EGFR, ERBB2, NRAS, and BRAF are early clonal genomic events during carcinogenesis of lung adenocarcinoma, whereas TP53 and cell mobility, gap junction, and metastasis-related genes may be late events associated with subclonal diversification and neoplastic progression. Genomic intratumor heterogeneity and immunoediting are common and early phenomena that may have occurred before the acquisition of invasion.
Authors: Emmet J Jordan; Hyunjae R Kim; Maria E Arcila; David Barron; Debyani Chakravarty; JianJiong Gao; Matthew T Chang; Andy Ni; Ritika Kundra; Philip Jonsson; Gowtham Jayakumaran; Sizhi Paul Gao; Hannah C Johnsen; Aphrothiti J Hanrahan; Ahmet Zehir; Natasha Rekhtman; Michelle S Ginsberg; Bob T Li; Helena A Yu; Paul K Paik; Alexander Drilon; Matthew D Hellmann; Dalicia N Reales; Ryma Benayed; Valerie W Rusch; Mark G Kris; Jamie E Chaft; José Baselga; Barry S Taylor; Nikolaus Schultz; Charles M Rudin; David M Hyman; Michael F Berger; David B Solit; Marc Ladanyi; Gregory J Riely Journal: Cancer Discov Date: 2017-03-23 Impact factor: 39.397
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245
Authors: Alex H Ramos; Lee Lichtenstein; Manaswi Gupta; Michael S Lawrence; Trevor J Pugh; Gordon Saksena; Matthew Meyerson; Gad Getz Journal: Hum Mutat Date: 2015-03-16 Impact factor: 4.878
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245
Authors: Alvin J X Lee; David Endesfelder; Andrew J Rowan; Axel Walther; Nicolai J Birkbak; P Andrew Futreal; Julian Downward; Zoltan Szallasi; Ian P M Tomlinson; Michael Howell; Maik Kschischo; Charles Swanton Journal: Cancer Res Date: 2011-03-01 Impact factor: 12.701
Authors: Hee-Jin Jang; Hyun-Sung Lee; Bryan M Burt; Wendong Yu; Maheshwari Ramineni; Cynthia Y Truong; Daniela Ramos; Taylor Splawn; Jong Min Choi; Sung Yun Jung; Ju-Seog Lee; Daniel Y Wang; Joel M Sederstrom; Massimo Pietropaolo; Farrah Kheradmand; Christopher I Amos; Thomas M Wheeler; R Taylor Ripley Journal: Cancer Res Date: 2022-07-18 Impact factor: 13.312
Authors: Hitoshi Dejima; Xin Hu; Runzhe Chen; Jiexin Zhang; Junya Fujimoto; Edwin R Parra; Cara Haymaker; Shawna M Hubert; Dzifa Duose; Luisa M Solis; Dan Su; Junya Fukuoka; Kazuhiro Tabata; Hoa H N Pham; Nicholas Mcgranahan; Baili Zhang; Jie Ye; Lisha Ying; Latasha Little; Curtis Gumbs; Chi-Wan Chow; Marcos Roberto Estecio; Myrna C B Godoy; Mara B Antonoff; Boris Sepesi; Harvey I Pass; Carmen Behrens; Jianhua Zhang; Ara A Vaporciyan; John V Heymach; Paul Scheet; J Jack Lee; Jia Wu; P Andrew Futreal; Alexandre Reuben; Humam Kadara; Ignacio I Wistuba; Jianjun Zhang Journal: Nat Commun Date: 2021-05-11 Impact factor: 14.919